Inicio>>Signaling Pathways>> Immunology/Inflammation>> Aryl Hydrocarbon Receptor>>Carbidopa (hydrate)

Carbidopa (hydrate)

Catalog No.GC47037

La carbidopa ((S)-(-)-Carbidopa) monohidrato, un inhibidor de la descarboxilasa periférica, se puede utilizar para la investigaciÓn de la enfermedad de Parkinson'.

Products are for research use only. Not for human use. We do not sell to patients.

Carbidopa (hydrate) Chemical Structure

Cas No.: 38821-49-7

Tamaño Precio Disponibilidad Cantidad
25 mg
41,00 $
Disponible
50 mg
77,00 $
Disponible
100 mg
147,00 $
Disponible
250 mg
327,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com


Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Carbidopa is a peripherally-restricted inhibitor of dopamine decarboxylase, the enzyme that converts L-DOPA to dopamine.1 Carbidopa (100 mg/kg) pretreatment in dog increases the plasma concentration of L-DOPA by 186% and prolongs the half-life in plasma by 48% and skeletal muscle extracellular fluid by 66%.2 Carbidopa also binds to and potentiates the activity of the aryl hydrocarbon receptor (AhR), which is a ligand-dependent transcription factor that mediates the toxicity of certain xenobiotics and polyaromatic hydrocarbons.3 It inhibits the proliferation of pancreatic cancer cells in vitro and tumor growth in vivo. Formulations containing carbidopa are used in combination with L-DOPA in the treatment of Parkinson's disease to increase the amount of dopamine in the brain and reduce peripheral side effects associated with L-DOPA administration.

1.Clark, W.G., Oldendorf, W.H., and Dewhurst, W.G.Blood-brain barrier to carbidopa (MK -486) and Ro 4-4602, peripheral dopa decarboxylase inhibitorsJ. Pharm. Pharmacol.25(5)416-418(1973) 2.Deleu, D., Sarre, S., Ebinger, G., et al.The effect of carbidopa on the pharmacokinetics and metabolism of intravenously administered levodopa in blood plasma and skeletal muscleNaunyn Schmiedebergs Arch. Pharmacol.348(6)576-581(1993) 3.Ogura, J., Miyauchi, S., Shimono, K., et al.Carbidopa is an activator of aryl hydrocarbon receptor with potential for cancer therapyBiochem J.474(20)3391-3402(2017)

Reseñas

Review for Carbidopa (hydrate)

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Carbidopa (hydrate)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.